{"id":530013,"date":"2026-07-07T18:58:10","date_gmt":"2026-07-07T18:58:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/530013\/"},"modified":"2026-07-07T18:58:10","modified_gmt":"2026-07-07T18:58:10","slug":"vitiligo-pipeline-update-teva-set-to-advance-its-anti-il-15-antibody-into-phase-2b-development","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/530013\/","title":{"rendered":"Vitiligo Pipeline Update: Teva Set To Advance Its Anti-IL-15 Antibody Into Phase 2b Development"},"content":{"rendered":"<p style=\"font-weight: 400;\">Teva Pharmaceutical Industries Ltd. is advancing TEV-\u2019408, an investigational anti-interleukin (IL)-15 monoclonal antibody, into Phase 2b development in vitiligo in the fourth quarter of 2026.<\/p>\n<p style=\"font-weight: 400;\">TEV-\u2019408 is designed for quarterly dosing.<\/p>\n<p style=\"font-weight: 400;\">The decision to advance development follows encouraging results from an ongoing Phase 1b, open-label study in adults with active or stable non-segmental vitiligo (NSV). The study showed improvements in skin pigmentation in patients with active or stable NSV.<\/p>\n<p style=\"font-weight: 400;\">In addition, TEV-\u2019408 was well-tolerated with no safety signals observed to date.<\/p>\n<p style=\"font-weight: 400;\">At baseline, 66% of enrolled participants had vitiligo affecting more than 10% of body surface area, representing a population with limited treatment options.<\/p>\n<p style=\"font-weight: 400;\">At Week 24, in evaluable participants:<\/p>\n<p>Nearly 75% of patients reported improvement in facial vitiligo, with half reporting \u201cmuch\u201d or \u201cvery much\u201d improved<br \/>\nFully 42% achieved Facial Vitiligo Area Scoring Index(F-VASI) 50 and 21% achieved F-VASI75<br \/>\nFifty-five percent of patients reported improvement in total body vitiligo<br \/>\nSeven percent achieved Total Vitiligo Area Scoring Index (T-VASI) 50<\/p>\n<p>                    <a href=\"#\" rel=\"nofollow\" onclick=\"window.print(); return false;\" title=\"Printer Friendly, PDF &amp; Email\"><br \/>\n                    <img decoding=\"async\" src=\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/05\/noun-pdf-749513-9B9B9B.png\" alt=\"Print Friendly, PDF &amp; Email\" class=\"pf-button-img\" style=\"height: 50px;\"\/><br \/>\n                    <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Teva Pharmaceutical Industries Ltd. is advancing TEV-\u2019408, an investigational anti-interleukin (IL)-15 monoclonal antibody, into Phase 2b development in&hellip;\n","protected":false},"author":2,"featured_media":530014,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[42,242011,43,242012,40,38,41,39,214371],"class_list":["post-530013","post","type-post","status-publish","format-standard","has-post-thumbnail","category-headlines","tag-headlines","tag-interleukin-15","tag-news","tag-tev-408","tag-top-news","tag-top-stories","tag-topnews","tag-topstories","tag-vitiligo"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/530013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=530013"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/530013\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/530014"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=530013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=530013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=530013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}